Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

Oncogene

Volumn 29, Issue 18, 2010, Pages 2616-2627

  Xu, L ^a   Nilsson, M B ^a   Saintigny, P ^a   Cascone, T ^a   Herynk, M H ^a   Du, Z ^a   Nikolinakos, P G ^a   Yang, Y ^a   Prudkin, L ^a   Liu, D ^a   Lee, J J ^a   Johnson, F M ^a   Wong, K K ^b   Girard, L ^c   Gazdar, A F ^c   Minna, J D ^c   Kurie, J M ^a   Wistuba, I I ^a   Heymach, J V ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

EGFR; HIF 1a; Invasiveness; MET; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; GENE AMPLIFICATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MICE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR;

EID: 77952238683     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.16     Document Type: Article

References (61)

1. Beadsmoore CJ, Screaton NJ. (2003). Classification, staging and prognosis of lung cancer. Eur J Radiol 45: 8-17.
2. Bergstrom JD, Westermark B, Heldin NE. (2000). Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259: 293-299.
3. Bredin CG, Liu Z, Klominek J. (2003). Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer Res 23: 4877-4884.
4. Ciardiello F, Tortora G. (2008). EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
5. Cooper CS, Tempest PR, Beckman MP, Heldin CH, Brookes P. (1986). Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts. EMBO J 5: 2623-2628.
6. Cuvier C, Jang A, Hill RP. (1997). Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 15: 19-25.
7. Damstrup L, Rude Voldborg B, Spang-Thomsen M, Brunner N, Skovgaard Poulsen H. (1998). In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78: 631-640.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
9. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246.
11. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697.
12. Hamada J, Nagayasu H, Takayama M, Kawano T, Hosokawa M, Takeichi N. (1995). Enhanced effect of epidermal growth factor on pulmonary metastasis and in vitro invasion of rat mammary carcinoma cells. Cancer Lett 89: 161-167.
13. Hirami Y, Aoe M, Tsukuda K, Hara F, Otani Y, Koshimune R et al. (2004). Relation of epidermal growth factor receptor, phosphory-lated-Akt, and hypoxia-inducible factor-1alpha in non-small cell lung cancers. Cancer Lett 214: 157-164.
14. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. (2003). Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374.
15. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK et al. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104: 12867-12872.
16. Ichimura E, Maeshima A, Nakajima T, Nakamura T. (1996). Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87: 1063-1069.
17. Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K et al. (2006). Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 119: 2750-2759.
18. Janne PA, Engelman JA, Johnson BE. (2005). Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234.
19. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K et al. (2006). The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495.
20. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. (2000). Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811.
21. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116.
22. Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M et al. (2006). Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J 25: 4650-4662.
23. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158.
24. Li C, Hung Wong W. (2001). Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2: RESEARCH0032.
25. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. (2004). dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20: 1233-1240.
26. Liu C, Tsao MS. (1993). In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas. Am J Pathol 142: 1155-1162.
27. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE et al. (2007). Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081-2088.
28. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. (2005). The antiepidermal growth factor receptor monoclonal antibody cetux-imab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441.
29. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
30. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206.
31. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J et al. (2007). c-Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis. Cancer Sci 98: 1006-1013
32. NCBI-GEO (2007). http://www ncbi.nlm.nih.gov/geo/.
33. Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, Nicotra MR et al. (1996). Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74: 1862-1868.
34. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
35. Pai R, Nakamura T, Moon WS, Tarnawski AS. (2003). Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 17: 1640-1647.
36. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
37. Pao W, Miller VA. (2005). Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568.
38. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. (1987). Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 84: 6379-6383.
39. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. (2006). Crosstalk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281: 25903-25914.
40. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361.
41. Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660.
42. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA et al (2005). Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481.
43. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. (2006). EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197-3204.
44. Qiao H, Hung W, Tremblay E, Wojcik J, Gui J, Ho J et al. (2002). Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86: 665-677.
45. Rosario M, Birchmeier W. (2003). How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13: 328-335.
46. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE. (2002). Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun 290: 197-203.
47. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
48. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. (2005). Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65: 6401-6408.
49. Shimazaki K, Yoshida K, Hirose Y, Ishimori H, Katayama M, Kawase T. (2003). Cytokines regulate c-Met expression in cultured astrocytes. Brain Res 962: 105-110.
50. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ. (1998). The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66: 1915-1918.
51. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H et al. (2006). Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 2316-2321.
52. Stabile LP, Lyker JS, Huang L, Siegfried JM. (2004). Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 11: 325-335.
53. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, OByrne KJ. (2004). Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111: 43-50.
54. Swinson DE, O'Byrne KJ. (2006). Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer 7: 250-256.
55. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537.
56. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A et al. (2005). Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 131: 707-711.
57. Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F et al. (2008). A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7: 952-960.
58. Yi S, Chen JR, Viallet J, Schwall RH, Nakamura T, Tsao MS. (1998). Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br J Cancer 77: 2162-2170. (Pubitemid 28263936)
59. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L et al. (2005). Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570.
60. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.
61. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E et al. (2006). Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10: 39-50.